

1/16





FIG. 1A



**g1ZD-GFP**

**env** **IRES**

... AGAGTACGAGCCATAGATAACGTTACTGGCC ...

**IRES** **GFP**

... CACGATAAATACCATGGCCATTTCGAACAAAGG ...

**GFP** **MLV NONCODING**

... CTGTACAAGTAGCGGCCGCGCCATAGATAAA ...

**g1ZD-hygro**

**env** **IRES**

... AGAGTACGAGCCATAGATAACGTTACTGGCC ...

**IRES** **hygromycin<sup>R</sup>**

... CACGATAAATACCATGGCCATTTCGAACCGCA ...

**hygromycin<sup>R</sup>** **MLV NONCODING**

... TGGGGGCCGCGCCATAGATAAAATAAAAGAT ...

FIG. 1B

10045178.011102

2/16




FIG. 2A




FIG. 2B

10045178.041102

3/16




FIG. 3A




FIG. 3B

4/16




FIG. 4

5/16




FIG. 5





FIG. 6A



6/16





FIG. 6B

7/16

**Negative Control**  
**group**

**Experimental**  
**group**


**RAT NMU BREAST CANCER CELL INJECTION**  
**(INITIAL INOCULUM:  $2 \times 10^6$  CELLS)**




**ESTABLISHMENT OF TUMORS (APPROX. 4 WEEKS)**

**g12D-GFP VIRUS INJECTION**  
**( $1 \times 10^4$  INFECTIOUS UNITS IN  $100 \mu\text{l}$ )**


**2 WEEKS POST-INJECTION OF VIRUS**



**4 WEEKS POST-INJECTION OF VIRUS**



**6 WEEKS POST-INJECTION OF VIRUS**



**FIG. 7**

201108254001

8/16




FIG. 8



9/16




FIG. 9A

10/16

201108151800T




FIG. 9B




FIG. 10




FIG. 11

13/16

20110708 21:51:00




FIG. 12




FIG. 13

14/16




FIG. 14




FIG. 15

15/16




FIG. 16A





FIG. 16B

2011FD.6TSHOOT

16/16

ZE-GFP



ZV-A-GFP






FIG. 17

WILD TYPE MLV ENVELOPE



ZDAH-emd



ZBAH-emd




FIG. 18